Sunday, May 18, 2025
Khmer Daily Cambodia News
34 °c
Phnom Penh
  • LATEST
  • CAMBODIA
  • ASIA
    • JAPAN
    • SOUTH KOREA
    • TAIWAN
  • WORLD
    • CHINA
    • RUSSIA
  • BUSINESS CAMBODIA
  • TECHNOLOGY
No Result
View All Result
  • LATEST
  • CAMBODIA
  • ASIA
    • JAPAN
    • SOUTH KOREA
    • TAIWAN
  • WORLD
    • CHINA
    • RUSSIA
  • BUSINESS CAMBODIA
  • TECHNOLOGY
No Result
View All Result
The Khmer Daily
No Result
View All Result
Home World

Pfizer, Moderna, Novavax COVID-19 vaccine: As lab execs sell shares worth millions, questions arise

November 17, 2020
in Health, World
0
Pfizer, Moderna, Novavax COVID-19 vaccine: As lab execs sell shares worth millions, questions arise
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

AFP – Pfizer, Moderna, Novavax: executives at several US laboratories developing COVID-19 vaccines have recently pocketed millions of dollars by selling shares in their companies, raising questions about the propriety of such a move in the midst of an international health crisis.

On the very day that pharmaceutical giant Pfizer announced preliminary data showing its vaccine was 90 percent effective against the Coronavirus, its chief executive Albert Bourla sold shares worth $5.6 million.

There was nothing illegal about this, Pfizer said: the sale took place according to rules allowing company heads to sell shares under predetermined criteria, at a date or for a price set in advance, to avoid any suspicion of insider training.

Under the same rules, several Moderna officials have sold shares worth more than $100 million in recent months.

That company has not placed a single product on the market since its creation in 2010, but the federal government has committed to paying it up to $2.5 billion if its vaccine proves effective.

Moderna shares have soared from $19 at the beginning of the year to a current level of $90.

The boss of Novavax, for his part, sold $4.2 million in shares on August 18, just over a month after the announcement it would receive public financing of $1.6 billion.

Accountable US, a nonpartisan taxpayers’ advocacy group, has calculated that from the start of the federally coordinated effort to develop vaccines on May 15 until August 31, officials at five pharmaceutical companies made more than $145 million by selling shares.

Executives at Pfizer and Moderna were operating under a rule put in place by the Securities and Exchange Commission in 2000 to allow company employees to sell shares without facing insider-trading charges.

It allows them to set up a plan determining the trades of their shares at a price, amount or dates specified in advance, but only when they are not in possession of privileged information that could affect share prices.

Once such a sale is planned, it cannot be modified at the last minute, even if its timing might ultimately raise questions.

Still, this use of the rule by Pfizer and Moderna appears “legally questionable”, according to Daniel Taylor, an associate professor at the University of Pennsylvania’s Wharton business school, who has been studying the big pharma firms since the beginning of the pandemic.

“The question is, what did the executives know at the time that they pre-scheduled the trade?” he asked.

Bourla, according to Pfizer, had merely re-authorized on August 19 a plan for a share sale originally authorized in February, “with the same price and volume term”.

But a day after that, the company issued a statement describing the preliminary results of its clinical trials as “positive”.

It is of course not just normal but desirable that laboratory heads should be encouraged to develop a safe and reliable vaccine as quickly as possible, Taylor said.

But “when they are going to sell their shares, they have to make sure that they are operating by the same level playing field, that they’re not taking advantage of other investors by having more information”, he said.

Taylor added a word of caution: “I don’t think that companies have internalised the reputational risk to these trades” by selling shares even as COVID-19 cases have been spiralling upward around the world.

When a top executive needs to sell shares to pay for a yacht, a new house or his children’s education, the public rarely is aware of it. But with the pandemic raging, the laboratories are under intense scrutiny.

For Sanjai Bhagat, a professor at the University of Colorado-Boulder who specialises in corporate governance, top executives should simply not be allowed to sell company shares until a year or two after they leave the company.

“If they have a lot of vested stock and stock options, then they have an incentive to get the share price as high as they can, even by not being totally honest with the investing public,” he said.

Bhagat believes corporate boards should eliminate any chance of temptation.

“Not having done anything illegal is not the standard by which they should be judged,” he said. “Especially in these times, people are expecting them to act responsibly.”

The SEC would not say whether it was investigating any of the lab executives.

But in an interview in May on the CNBC network, SEC chairman Jay Clayton exhorted executives to respect best practices.

“Why would you want to even raise the question that you were doing something that was inappropriate?” he asked.

This article was first published in Khmer Times. All contents and images are copyright to their respective owners and sources.

Tags: COVID-19 vaccineModernaNovavaxPfizer
Previous Post

Australia back on outbreak alert as state reports jump in virus cases

Next Post

Stray dog helps nab 2 alleged drug dealers in Thailand

Related Posts

Italy to pass ‘right to be forgotten’ law for cancer survivors

Italy to pass ‘right to be forgotten’ law for cancer survivors

by AsiaOne
June 15, 2023
0
24

ROME — Italy will pass a law on the "right to be forgotten" (RTBF) for cancer survivors, Prime Minister Giorgia Meloni...

Bill Gates in China: Microsoft co-founder to meet Xi Jinping

Bill Gates in China: Microsoft co-founder to meet Xi Jinping

by AsiaOne
June 15, 2023
0
38

HONG KONG — Bill Gates, Microsoft Corp's co-founder, is set to meet Chinese President Xi Jinping on Friday (June 16) during his...

US judge temporarily blocks Microsoft acquisition of Activision

US judge temporarily blocks Microsoft acquisition of Activision

by AsiaOne
June 15, 2023
0
29

WASHINGTON - A US judge late on Tuesday (June 13) granted the Federal Trade Commission's (FTC) request to temporarily block Microsoft...

Most Popular

$2 million electric motorbike assembly plant in Cambodia by Verywords Co Ltd launched

$2 million electric motorbike assembly plant in Cambodia by Verywords Co Ltd launched

May 30, 2023
48
EZECOM first to collaborate with AWS to provide leading Cloud service for Cambodia

EZECOM first to collaborate with AWS to provide leading Cloud service for Cambodia

March 15, 2022
43
Innovation key to Cambodia’s garment industry growth

Innovation key to Cambodia’s garment industry growth

December 3, 2021
17
Ford Cambodia, operated by RMA Cambodia, brings vehicles and technical training

Ford Cambodia, operated by RMA Cambodia, brings vehicles and technical training

September 1, 2020
56
Celimo Tires to invest $300 million in Sihanoukville Special Economic Zone in Cambodia

Celimo Tires to invest $300 million in Sihanoukville Special Economic Zone in Cambodia

December 20, 2021
30
Cambodia Rice price could rise up to 20 percent in coming months

Cambodia Rice price could rise up to 20 percent in coming months

May 25, 2022
60

© 2020 By Khmer Daily News

No Result
View All Result
  • Home
  • Latest
  • Cambodia
  • ASIA
  • World
  • Business
  • Tech

© 2019 The Khmer Daily.

error: Content is protected !!